Anti-IL-1RAP ScFv-mSA-S19-TAT Fusion Carrier As a Multifunctional Platform for Versatile Delivery of Biotinylated Payloads to Myeloid Leukemia Cells

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 24

PMID 39443595

Authors

Aref Farokhi-Fard

Saman Rahmati

Negin Sadat Hashemi Aval

Farzaneh Barkhordari

Elham Bayat

Samira Komijani

Hooman Aghamirza Moghim Aliabadi

Fatemeh Davami

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is an aggressive blood cancer with frequently poor clinical outcomes. This heterogeneous malignancy encompasses genetically, molecularly, and even clinically different subgroups. This makes it difficult to develop therapeutic agents that are effective for all subtypes of the disease. Therefore, a selective, universal, and adaptable delivery platform capable of carrying various types of anti-neoplastic agents is an unmet requirement in this area. Two multifunctional fusion proteins were designed for the delivery of biotinylated cargoes to human myeloid leukemia cells by fusing an anti-IL-1RAP single-chain antibody with streptavidin (tetramer or monomer), a cell-penetrating peptide (CPP), and an endosomolytic peptide in a single biomacromolecule. The designed fusions were analyzed primarily in silico, and the biofunctionality of the selected fusion was fully characterized via several binding assays, hemolysis assay, confocal microscopy and cell cytotoxicity assay after production via the Escherichia coli (E. coli) system. The refolded protein exhibited desirable binding activity to leukemic cells, pure antigen and biotinylated BSA. Further analyses revealed efficient cellular uptake, endosomolytic activity, and nuclear penetration without any detectable cytotoxicity toward normal epithelial cells. The described platform seems to have great potential for targeted delivery of different therapeutics to malignant myeloid cells.

References

Li F, Zhang W, Wang M, Jia P . IL1RAP regulated by PRPRD promotes gliomas progression via inducing neuronal synapse development and neuron differentiation in vitro. Pathol Res Pract. 2020; 216(11):153141. DOI: 10.1016/j.prp.2020.153141. View

Trad R, Warda W, Alcazer V, Neto Da Rocha M, Berceanu A, Nicod C . Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022; 10(7). PMC: 9272123. DOI: 10.1136/jitc-2021-004222. View

Liu Y, Bewersdorf J, Stahl M, Zeidan A . Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. Blood Rev. 2018; 34:67-83. DOI: 10.1016/j.blre.2018.12.001. View

Reilly A, Kersun L, Prak E, Boyer J, McDonald K, Jawad A . Immunologic consequences of chemotherapy for acute myeloid leukemia. J Pediatr Hematol Oncol. 2012; 35(1):46-53. PMC: 3526680. DOI: 10.1097/MPH.0b013e318266c0c8. View

Rahmati S, Bagherzadeh K, Arab S, Torkashvand F, Amanlou M, Vaziri B . Computational designing of the ligands of Protein L affinity chromatography based on molecular docking and molecular dynamics simulations. J Biomol Struct Dyn. 2023; 42(22):12282-12292. DOI: 10.1080/07391102.2023.2268219. View

Heo L, Park H, Seok C . GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 2013; 41(Web Server issue):W384-8. PMC: 3692086. DOI: 10.1093/nar/gkt458. View

Wu X, Wang F, Yang X, Gong Y, Niu T, Chu B . Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia. Small. 2024; 20(42):e2403409. DOI: 10.1002/smll.202403409. View

Boado R, Zhang Y, Zhang Y, Xia C, Wang Y, Pardridge W . Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem. 2008; 19(3):731-9. DOI: 10.1021/bc7004076. View

Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M . Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy. J Clin Oncol. 2021; 39(5):419-432. PMC: 8078464. DOI: 10.1200/JCO.20.00475. View

10.

Le Dieu R, Taussig D, Ramsay A, Mitter R, Miraki-Moud F, Fatah R . Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009; 114(18):3909-16. PMC: 2773481. DOI: 10.1182/blood-2009-02-206946. View

11.

Nakamura M, Fujiwara K, Doi N . Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide. J Nanobiotechnology. 2022; 20(1):458. PMC: 9615171. DOI: 10.1186/s12951-022-01667-4. View

12.

Zhang H, Hughes C, Li W, He J, Surdez D, El-Naggar A . Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. Cancer Discov. 2021; 11(11):2884-2903. PMC: 8563374. DOI: 10.1158/2159-8290.CD-20-1690. View

13.

Barreto I, DE Pinho Pessoa F, Machado C, da Costa Pantoja L, Ribeiro R, Lopes G . Leukemic Stem Cell: A Mini-Review on Clinical Perspectives. Front Oncol. 2022; 12:931050. PMC: 9270022. DOI: 10.3389/fonc.2022.931050. View

14.

Cheal S, Chung S, Vaughn B, Cheung N, Larson S . Pretargeting: A Path Forward for Radioimmunotherapy. J Nucl Med. 2022; 63(9):1302-1315. DOI: 10.2967/jnumed.121.262186. View

15.

Lim K, Huang H, Pralle A, Park S . Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol Bioeng. 2012; 110(1):57-67. DOI: 10.1002/bit.24605. View

16.

Shallis R, Wang R, Davidoff A, Ma X, Zeidan A . Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019; 36:70-87. DOI: 10.1016/j.blre.2019.04.005. View

17.

Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M . Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A. 2010; 107(37):16280-5. PMC: 2941341. DOI: 10.1073/pnas.1004408107. View

18.

Maxfield F, Yamashiro D . Endosome acidification and the pathways of receptor-mediated endocytosis. Adv Exp Med Biol. 1987; 225:189-98. DOI: 10.1007/978-1-4684-5442-0_16. View

19.

Modanloo Jouybari R, Sadeghi A, Khansarinejad B, Sadoogh Abbasian S, Abtahi H . Production of Recombinant Streptavidin and Optimization of Refolding Conditions for Recovery of Biological Activity. Rep Biochem Mol Biol. 2018; 6(2):178-185. PMC: 5940357. View

20.

Sudo K, Niikura K, Iwaki K, Kohyama S, Fujiwara K, Doi N . Human-derived fusogenic peptides for the intracellular delivery of proteins. J Control Release. 2017; 255:1-11. DOI: 10.1016/j.jconrel.2017.03.398. View